In recent years, immune checkpoint inhibitors (ICIs) such as cytotoxic T‐lymphocyte antigen 4 (CTLA‐4), programmed death‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) inhibitors have revolutionised the treatment landscape of NSCLC.2, 3, 4, 5, 6. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.